Archived tissue samples from people with t(4;14) multiple myeloma, studied for biomarkers
Checks whether stored samples from adults with t(4;14) multiple myeloma can reveal biomarkers.
Key facts
- Who runs it
- BIWAKO
- Where
- Lyon, FranceSee the site
- Trial code
- Registry title
- Multiple Myeloma t(4 ;14) FFPE Samples
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- 5 Jul 2026
- Expected to end
- 1 Jun 2027
- Type of study
- Observational
- Record updated
- 19 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at archived tissue samples from adults with multiple myeloma that has the t(4;14) translocation. No new treatment is given.
- Age
- Adults, 18 years and older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma confirmed under the microscope, diagnosed within the past 10 years
- Biomarker or test result
- t(4;14) translocation
Main reasons for not taking part
- Samples taken from bone lesions
- Too little or non-representative stored tissue (FFPE) material
- Missing key diagnostic or clinical data
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients with histologically confirmed myeloma with a t(4;14) translocation
- Availability of a representative FFPE block from a surgical specimen
- Diagnosis established within the past 10 years
- Availability of associated clinical and follow-up data
Who cannot take part
- Bone lesions samples
- Insufficient or non-representative FFPE material
- Missing key diagnostic or clinical data
Where in France
- BIWAKOLyon, FranceContact: Marie BREVETNo longer taking part
About the trial
What the trial wants to find out
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with 4;14 translocated multiple myeloma, together with their associated clinical and pathological data. The study will determine whether these archived samples are suitable for exploratory biomarker assessment.
Read full original descriptionShow less
No intervention is performed. All FFPE samples and clinical data originate exclusively from routine diagnostic procedures and will be analyzed retrospectively for research purposes.
The group in the trial
- FFPE samples
Samples obtained from patients with multiple myeloma disease and confirmed 4;14 translocation. Tissu samples should be obtained (nos aspirate)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Discovery And Validation Of New Biomarkers In The Context Of Multiple Myeloma With t(4-14) and Relapse
- Plain-language title
- Archived tissue samples from people with t(4;14) multiple myeloma, studied for biomarkersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 March 2026